ASX:TLX 8 June 2026 - 12 June 2026

Telix Pharmaceuticals stock draws attention after STOXX index move ahead of FDA catalysts
·

Telix Pharmaceuticals stock draws attention after STOXX index move ahead of FDA catalysts

Telix Pharmaceuticals Limited starts the week with investors keeping an eye on a possible index flow, while concerns about regulatory risk remain high. Shares of the radiopharma firm on the ASX finished Friday at A$13.60, up 0.97% for the session. That lagged the S&P/ASX 200, which rose 1.98%. Telix has climbed 6.34% over the last four weeks but is still down 45.12% over 12 months. The stock stays volatile, moving on any fresh signs of institutional interest or regulatory news. Telix will be added to multiple STOXX health-care indexes after the June 13 STOXX index review. Changes take effect June 22 and include the STOXX Asia/Pacific 600 Health Care, STOXX Global 1800 Health Care, and related benchmarks. Index changes like
June 14, 2026
Telix Pharmaceuticals Rallies on ASX, Healthcare Stocks in Focus Before FDA Decision
·

Telix Pharmaceuticals Rallies on ASX, Healthcare Stocks in Focus Before FDA Decision

Sydney, June 13, 2026, 04:07. Telix Pharmaceuticals Limited closed at A$13.60 in Sydney, climbing 0.97% after gaining A$0.13 for the day. Shares traded between A$13.32 and A$13.99. The session saw a firm rally in the S&P/ASX 200, which jumped 1.98%. Telix tracked the market higher but trailed the broader advance as investors considered its busy regulatory calendar against improving risk sentiment.
June 12, 2026
Telix shares top ASX 200, traders eye TLX moves
·

Telix shares top ASX 200, traders eye TLX moves

Telix Pharmaceuticals looked to outperform the market at the ASX pre-open Wednesday. Shares closed up 0.6% at A$13.39 Tuesday, with the day’s range between A$12.80 and A$13.50. Volume came in around 2.14 million. Telix's market cap sits near A$4.54 billion. The stock is still trading below its 52-week high of A$26.25, but above the A$8.26 low. The move is notable since the wider Australian market dropped. The S&P/ASX 200 shed 0.24% to end at 8,604.20 on Tuesday. Healthcare stocks offered some support after a steep selloff at the open.
June 10, 2026
Telix Rallied Before the ASX Closed; Tuesday Trading in Focus
·

Telix Rallied Before the ASX Closed; Tuesday Trading in Focus

Telix Pharmaceuticals heads into the shortened Australian trading week with new momentum. Shares climbed on Friday, moving against a weaker market. Investors are again watching the company’s cancer-imaging and therapy pipeline. No Monday trade means the next test for the stock comes after the holiday. Investors will be looking at Friday’s rebound and weighing it against a global risk-off mood that followed a big drop in U.S. stocks. Friday’s jobs data revived interest rate fears.
June 8, 2026